Citigroup Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Geoff Meacham maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $42 to $50.
Citigroup analyst Geoff Meacham maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $42 to $50.